| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
118,610,000 |
| Market
Cap: |
23.41(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1974 - $0.2732 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Oncocyte is a molecular diagnostics company focused on developing and commercializing proprietary laboratory-developed tests to serve unmet medical needs across the cancer care continuum. Co.'s DetermaRx™ is a predictive molecular test for early-stage adenocarcinoma of the lung. This test provides information that a physician can use to help identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer who are at high-risk of recurrence and may benefit from chemotherapy. Co.'s portfolio includes a gene expression-based test called DetermaIO™, which is being developed to identify patients most likely to respond to immunotherapy drugs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
2,457,288 |
2,457,288 |
2,487,288 |
30,608,426 |
| Total Buy Value |
$7,167,688 |
$7,167,688 |
$7,174,135 |
$15,854,134 |
| Total People Bought |
3 |
3 |
4 |
10 |
| Total Buy Transactions |
4 |
4 |
5 |
20 |
| Total Shares Sold |
0 |
0 |
0 |
107,514 |
| Total Sell Value |
$0 |
$0 |
$0 |
$111,901 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Griffith Melinda |
Director |
– • – |
2022-06-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Kingsley Alfred D |
Director |
– • – |
2022-06-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
394,111 |
|
- |
|
| Kamen Efrem |
10% Owner |
– – • |
2022-06-24 |
4 |
S |
$1.03 |
$102,635 |
I/I |
(99,386) |
8,479,682 |
|
33% |
|
| Yu Li |
VP Cntrllr/Prncpl Acctng Offcr |
• – – |
2022-05-18 |
4 |
S |
$1.14 |
$9,266 |
D/D |
(8,128) |
16,872 |
|
34% |
|
| Yu Li |
VP Cntrllr/Prncpl Acctng Offcr |
• – – |
2022-05-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
| Kamen Efrem |
10% Owner |
– – • |
2022-04-14 |
4/A |
B |
$1.23 |
$250,350 |
I/I |
200,000 |
8,532,663 |
1.5 |
- |
|
| Kamen Efrem |
10% Owner |
– – • |
2022-04-14 |
4 |
B |
$1.23 |
$7,887,850 |
I/I |
5,931,707 |
1,381,438 |
1.5 |
-29% |
|
| Ross Douglas T. |
Chief Scientific Officer |
• – – |
2022-03-25 |
4 |
B |
$1.40 |
$21,000 |
D/D |
15,000 |
20,317 |
2.74 |
-30% |
|
| Paulsen Gisela |
Chief Operating Officer |
• – – |
2022-03-17 |
4 |
B |
$1.20 |
$19,767 |
D/D |
16,500 |
16,500 |
2.74 |
-37% |
|
| Andrews Ronald Asbury |
Chief Executive Officer |
• • – |
2022-03-16 |
4 |
B |
$1.28 |
$64,150 |
D/D |
50,000 |
293,212 |
2.81 |
-30% |
|
| Redmond Cavan M. |
Director |
– • – |
2022-03-16 |
4 |
B |
$1.19 |
$47,560 |
D/D |
40,000 |
110,863 |
2.39 |
-30% |
|
| Levine Mitchell S |
Chief Financial Officer |
• – – |
2022-03-15 |
4 |
B |
$1.17 |
$29,150 |
D/D |
25,000 |
87,080 |
2.74 |
-26% |
|
| Bradsher Neal C |
10% Owner |
– – • |
2021-09-23 |
4 |
OE |
$0.00 |
$0 |
I/I |
0 |
17,349,945 |
|
- |
|
| Bradsher Neal C |
10% Owner |
– – • |
2021-09-23 |
4 |
OE |
$3.15 |
$1,807,836 |
D/D |
573,461 |
17,349,945 |
|
- |
|
| Andrews Ronald Asbury |
Chief Executive Officer |
• • – |
2021-07-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,834) |
243,212 |
|
- |
|
| Andrews Ronald Asbury |
Chief Executive Officer |
• • – |
2021-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
65,000 |
259,046 |
|
- |
|
| Andrews Ronald Asbury |
Chief Executive Officer |
• • – |
2021-06-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(25,873) |
194,046 |
|
- |
|
| Last Andrew J. |
Director |
– • – |
2021-06-11 |
4 |
OE |
$3.00 |
$20,979 |
D/D |
6,993 |
30,170 |
|
- |
|
| Andrews Ronald Asbury |
Chief Executive Officer |
• • – |
2021-05-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
106,221 |
219,919 |
|
- |
|
| Levine Mitchell S |
Chief Financial Officer |
• – – |
2021-04-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,620) |
62,080 |
|
- |
|
| Levine Mitchell S |
Chief Financial Officer |
• – – |
2021-04-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
66,700 |
|
- |
|
| Andrews Ronald Asbury |
Chief Executive Officer |
• • – |
2021-03-19 |
4 |
B |
$4.79 |
$52,702 |
D/D |
11,000 |
113,698 |
2.81 |
11% |
|
| Bradsher Neal C |
10% Owner |
– – • |
2021-02-05 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
16,776,484 |
1.42 |
-6% |
|
| Bradsher Neal C |
10% Owner |
– – • |
2021-02-05 |
4 |
B |
$4.50 |
$2,700,000 |
D/D |
600,000 |
16,776,484 |
2.45 |
-6% |
|
| Bradsher Neal C |
10% Owner |
– – • |
2021-01-20 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
16,176,484 |
1.42 |
12% |
|
142 Records found
|
|
Page 3 of 6 |
|
|
